Mercer Global Advisors
PRLD icon

Mercer Global Advisors’s Prelude Therapeutics PRLD Stock Holding History

Mercer Global Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27 Buy
+5
New +$22 ﹤0.01% 6035

Other funds holding PRLD

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Mercer Global Advisors's PRLD Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 5 shares worth $27. The stake represents ﹤0.01% of the portfolio and ranks #6035 among its holdings.

26 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Mercer Global Advisors held 5 shares of Prelude Therapeutics worth $27 as of Q2 2026.
  • Prelude Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #6035 holding.
  • 26 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.